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Background and Purpose: Intracranial atherosclerotic disease (ICAD) is a common
cause of stroke worldwide. Although there are different endovascular options for the
treatment of symptomatic ICAD (sICAD), it is still controversial. Herein, we aim to study
the safety and efficacy of a new generation of drug-eluting balloon-mounted stent (DES);
Resolute (R) onyx DES in the treatment of sICAD.
Methods: A prospectively maintained neuroendovascular procedures database in a
high-volume comprehensive stroke center was reviewed from October 2019 through
January 2020. Patients were included if they had sICAD (≥70% stenosis), failed medical
management, and underwent intracranial stenting with R-onyx DES. Technical success
was defined as the ability to deploy the device at the desired location and achievement
of <30% residual stenosis. The primary outcome was the occurrence of complications
within 72 h of the procedure (strokes, ischemic or hemorrhagic; andmortality). Secondary
outcomes included rates of symptomatic and angiographic recurrence within 6 months
of the procedure.
Results: A total of 18 consecutive patients (mean age, 66.6 years; 44.4%
were females and 94.4% were Hispanic) were eligible for the analysis. Indication
for treatment was recurrent strokes in 13 and recurrent transient ischemic attack
(TIA) in 5. A total of 22 symptomatic lesions with a mean baseline stenosis
percent (84.9 ± 9.6) were treated using 23 R-onyx DES in 19 procedures. All
procedures were done under general anesthesia with 100% technical success, and
no reported periprocedural strokes or death. Among 13 patients who had clinical
follow-up, 1 (7.7%) patient had TIA. There were no reported ischemic or hemorrhagic
strokes. Angiographic follow-up for 9 (50%) patients showed no in-stent restenosis.
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Conclusion: The use of R-onyx DES in the treatment of sICAD is safe with high
technical success rates. Large prospective multicenter trials with long-term follow-up
are warranted.
Keywords: intracranial atherosclerosis, angioplasty, stenting, drug eluting stent, stroke
INTRODUCTION
Intracranial atherosclerotic disease (ICAD) is a common cause of
stroke worldwide, with variable prevalence among different races
(1). Endovascular treatment (ET) has been controversial since
the results of randomized clinical trials (RCTs) that compared
medical treatment (MT) vs. ET, Stenting vs. Aggressive Medical
Management for Preventing Recurrent stroke in Intracranial
Stenosis (SAMMPRIS) (2), and Vitesse Intracranial Stent Study
for Ischemic Stroke Therapy (VISSIT) (3) trials were terminated
in advance because ET groups showed a significant increase in
perioperative complications. On the other hand, a single-center
RCT in China (4) found that ET could be a safe and efficient
treatment modality for carefully selected patients with ICAD due
to middle cerebral artery stenosis. The Wingspan Stent System
Post Market Surveillance (WEAVE) trial (5) reported improved
safety of intracranial stenting with a periprocedural event rate of
stroke or death of 2.6% when stenting was performed using the
Food and Drug Administration (FDA)–approved indication and
by experienced operators. Different types of stents can be used
in intracranial stenting: self-expandable stent (SES) (5, 6) and
drug-eluting balloon-mounted stents (DES) (7–11). The former
has a lower radial force; therefore, it is less suitable to achieve
the ideal luminal dilatation, especially in those with calcified
lesions and has higher rates of in-stent restenosis (ISR) (12, 13).
Although DES reduces the risk of ISR (14) “by delivering an
antiproliferative drug that prevents neointimal hyperplasia,” the
delivery system is usually stiff, hence navigation along tortuous
intracranial vasculature could be difficult. Two generations of
DES have evolved according to their antiproliferative agents,
the first generation (paclitaxel/sirolimus-eluting stents) and
the second generation (everolimus/zotarolimus-eluting stents),
where the stent is more flexible than the latter.
In the present study, we aim to evaluate the safety and efficacy
of a new generation of DES, Resolute (R) onyx DES (Medtronic,
Santa Rosa, CA) in the treatment of sICAD.
MATERIALS AND METHODS
Patient Selection
We retrospectively reviewed a prospectively maintained
neuroendovascular procedures database in a comprehensive
stroke center from October 2019 through January 2020.
Patients were included in the analysis if they had sICAD: ≥70%
intracranial stenosis, recurrent strokes, or transient ischemic
attacks (TIAs) in the territory of the affected artery despite
aggressive MT2 and baseline modified Rankin Scale (mRS) ≤3.
The Institutional Review Board approved the study and written
informed consent was obtained from all participants to use the
off-label stent.
Device Description
R-onyx DES (Medtronic) Zotarolimus-Eluting Coronary Stent
System consists of a balloon-expandable, intracoronary DES
premounted on a Rapid Exchange or an Over-the-Wire stent
delivery system. R-onyx DES is manufactured from a composite
material of cobalt alloy and 90% platinum−10% iridium alloy
and is formed from a single wire bent into a continuous
sinusoid pattern that then laser fused back onto itself. The
stents are available in multiple lengths and diameters. The
delivery system has two radiopaque markers to aid in the
placement of the stent during fluoroscopy and is compatible with
0.014-in. (0.36-mm) guidewires and 1.42-mm (5 Fr/0.056 in.)
minimum inner diameter guide catheters. The strut thickness is
81µm. R-Onyx has a swaged shape and a larger strut width-to-
thickness ratio than the old generation (Resolute). Zotarolimus
dose density and polymer are identical to the Resolute DES;
however, because of the modified stent geometry, the overall
drug load is slightly reduced in most sizes of the R-Onyx
DES (15).
Endovascular Procedure
The decision to pursue with endovascular treatment was based on
multidisciplinary discussion between vascular neurologists and
neurointerventionalists. All procedures were performed under
general anesthesia. A dose of 325mg of acetylsalicylic acid (ASA)
and 75mg of clopidogrel was given at least 3 days before ET.
Platelet function was assessed by P2Y12 reaction units (PRU)
test with a target of 60–200; if it was above 200, a loading
dose (180mg) of ticagrelor was given then the patient was
started on ticagrelor 90mg BID and ASA 81mg daily and
discontinued clopidogrel. Femoral access was used for anterior
circulation lesions, whereas posterior circulation lesions were
approached through radial access. Two types of guiding catheters
were used: ballast long sheath (Balt, Irvine, CA, USA) and
Neuron 088 Max (Penumbra, Alameda, CA, USA), and the
choice between the two devices was depending on operator’s
preference. Similarly, two types of distal access catheters were
used: Navien 5Fr (Medtronic, Irvine, CA, USA) and Sofia 5Fr
(MicroVention, Tustin, CA, USA). During the intervention, all
patients were heparinized to activated clotting time from 250
to 300 s. A radiologic examination of the targeted vessel was
performed using a biplane angiographic system (Innova IGS
630; GE Healthcare, Chalfont St Giles, UK), the vessel diameter
adjacent to the stenosis and the diameter and length of the
stenosis were determined for proper selection of the stent size.
The degree of percent stenosis was determined as follows: percent
stenosis= [(1 – (Dstenosis/Dnormal))]× 100, where Dstenosis = the
diameter of the artery at the site of the most severe stenosis and
Dnormal = the diameter of the proximal normal artery (16).
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FIGURE 1 | Anterior–posterior projection of digital subtraction angiography shows (A) tandem intracranial significant stenoses of the left middle cerebral artery; distal
M1 segment (arrowhead) and superior division of M2 segment (arrow), (B) post-angioplasty and stenting with no residual stenosis using 2 Resolute Onyx Drug-Eluting
Stents 2 × 8mm.
Under a road map, the vessel distal to the stenosis was
catheterized with a microwire; in case of near occlusion of the
targeted vessel, a pre-dilatation with a balloon (Gateway; Stryker,
Kalamazoo, MI, USA) was performed, then the R-onyx DES was
deployed at nominal pressure (12 atm) with a manometer. After
deflation and withdrawal of the balloon catheter, a final DSA
run was carried out to confirm stent deployment at the targeted
stenosis and to exclude complications.
Dual antiplatelet therapy with either ticagrelor 90mg plus
ASA 81mg or clopidogrel 75mg plus ASA 81mg continues
indefinitely after the procedure.
Outcome and Follow-Up
The primary outcome was the incidence of strokes (ischemic,
hemorrhagic) and death within 72 h post-stenting which was
assessed clinically before patient discharge by a vascular
neurologist and radiologically through head CT. Technical
success was defined as the ability to deploy the device at the
desired location and achievement of <30% residual stenosis.
Patients underwent clinical and angiographic follow-up within
6 months after the procedure to assess for symptomatic and
angiographic recurrence.
Statistical Analysis
Categorical variables were expressed as frequencies and
percentages. After normality testing through Shapiro–Wilk,
continuous variables were expressed as mean ± SD for
parametric and as median for non-parametric variables. The
analysis was performed using SPSS 26 software (IBM, Armonk,
NY, USA).
RESULTS
A total of 18 patients were eligible for the analysis. The mean
age was 66.6 ± 12 years, 44.4% were females, and 94.4% were
Hispanic. Stroke risk factors included hypertension in all patients
(100%), diabetes mellitus in 12 (66.7%), hyperlipidemia in 9
(50%), and current cigarette smoking in 2 (11.1%). Moreover,
72.8% had recurrent strokes in the territory of the affected blood
vessel, and 27.8% had recurrent TIA. Nineteen symptomatic
lesions were treated with a mean baseline stenosis of 84.9± 9.6%.
Also, 72.7% of the lesions located in the anterior circulation and
27.3% in the posterior circulation. Tandem intracranial lesions
occurred in 16.7% of patients (Figure 1, Table 1).
A total of 19 procedures were performed under general
anesthesia with median fluoroscopy time 12.2 (10–18.3) min;
mean contrast volume, 50.4± 24ml. Themedian time of stenting
from the last stroke was 4.5 (1.8–67.5) days, with 10 (52.6%)
patients being treated within 7 days of the last stroke. The lesion
was accessed through a femoral puncture in 15 (78.9%) and
radial puncture in 4 (21.1%) of the procedures. Pre-dilatation
with a balloon was performed in four (21.1%) procedures. In-
stent thrombosis occurred in one procedure, which was resolved
with intra-arterial tirofiban without complications. A total of 23
stents were deployed, 1.3 per procedure and 9 (39.1%) were 2 ×
8mm in size. The overall procedural success rate was 100%, with
no reported periprocedural ischemic or hemorrhagic strokes and
death (Table 2).
Clinical and Angiographic Follow-Up
Among 13 patients who had clinical follow-up, one (7.7%)
patient had transient ischemic attack in the same territory of
the treated artery 2 months after the procedure. There were
no reported ischemic/hemorrhagic strokes or medication-
related complications. Nine (50%) patients underwent
digital subtraction angiography on follow-up and showed
no ISR (Table 2).
DISCUSSION
We successfully treated 18 patients with sICAD using the
Medtronic Resolute Onyx drug-eluting balloon-mounted stent.
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TABLE 1 | Patients’ demographics, risk factors, and lesion characteristics.
All patients n (%) n = 18






Diabetes mellitus 12 (66.7)
Hyperlipidemia 9 (50)
Current cigarette smoking 2 (11.1)
Recurrent stroke 13 (72.2)
Recurrent TIA 5 (27.8)
Total lesions n (%) n = 22
Stenosis location
Anterior circulation: 16 (72.7)
Supraclinoid ICA 3 (13.6)
Cavernous ICA 3 (13.6)
Petrous ICA 2 (9.1)
Middle cerebral artery
M1 segment 4 (18.2)
M2 segment 4 (18.2)
Posterior circulation: 6 (27.3)
Vertebral artery V4 segment 3 (13.6)
Basilar artery 2 (9.1)
Posterior cerebral artery 1 (4.5)
Tandem intracranial lesions per subject 3 (16.7)
Baseline stenosis percent (%) mean ± SD 84.9 ± 9.6
ICA, internal carotid artery; TIA, transient ischemic attack.
There was no periprocedural stroke or death within 72 h of
stenting. Moreover, there were no reported cases of ISR among
patients who had 6-month angiographic follow-up.
Currently, the Wingspan stent (Stryker) is the only FDA-
approved stent for the treatment of sICAD under the strict
indications applied in the WEAVE trial (5). Other applications
of ET for sICAD include balloon angioplasty alone (17) or
followed by SES (6), DES (7–11), and more recent use of a drug-
eluting balloon (18). Angioplasty alone without stent placement
is associated with higher rates of restenosis and procedural
complications due to the elastic recoil of blood vessels and the
risk of dissection (19).
The present case series reported high safety and technical
success in the treatment of sICAD using the most recent
generation of DES. R-onyx DES not only delivers zotarolimus
with “a more potent with less systemic side effect than first-
generation antiproliferative” (20) but also the stent geometry
is different from the old generation [Resolute and previously
studied Resolute Integrity (21)]. It has a swaged shape and
thinner struts that substantially improve stent navigability
while maintaining radial strength and lower overall drug
load. These advantages, in addition to the use of a more
biocompatible polymer, may improve the safety concern about
TABLE 2 | Procedural characteristics and outcome.
Procedural characteristics n (%) n = 19
Time of stenting from the last stroke (days) median (IQR) 4.5 (1.8–67.5)




General anesthesia 19 (100)
IA-tirofiban 1 (5.3)
R-onyx DES: n = 23
Stent per procedure 1.3
Stent size:
2×8mm 9 (39.1)
Number of lesions planned for treatment
1 16 (84.2)
2 3 (15.8)
Pre-stenting balloon angioplasty 4 (21.1)
Technical success 19 (100)
No residual stenosis 15 (78.9)
Non-significant residual stenosis 4 (21.1)
Total contrast (ml) mean ± SD 50.4 ± 24
Fluoroscopy time (min) median (IQR) 12.2 (10–18.3)
Outcome
Procedural complication
In-stent thrombosis 1 (5.3)
Ischemic stroke 0 (0)




Ischemic and hemorrhagic strokes 0 (0.0)
6-month angiogram (9 patients)
In-stent stenosis 0 (0.0)
IQR, interquartile range; TIA, transient ischemic attack.
late stent thrombosis (ST) with first-generation DES, which
results from incomplete re-endothelialization and persistent
fibrin deposition (22).
Periprocedural complications related to DES implantation
could result from high-degree stenosis of the target vessel,
difficult navigability of the stent due to its stiff nature especially
in the elderly with tortuous anatomy, and in more distal lesions,
deployment of the stent near a perforator and early treatment
within 7 days after stroke that may cause reperfusion hemorrhage
from the weakened capillary bed and recurrent stroke due to
rupture of unstable plaque (23).
Ye et al. (24) reported a 1.4% incidence of stroke or mortality
within 30 days after DES implantation in a group with moderate
stenosis <70% that increases to 12.1% if the stenosis was >70%.
The present study demonstrated no periprocedural strokes or
death with 84.9± 9.6%mean baseline stenosis and deployment of
the R-onyx DES in different types of lesions; anterior circulation
72.7%, posterior circulation 27.3%, and tandem intracranial
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FIGURE 2 | Anterior–posterior projection of digital subtraction angiography shows (A) significant stenosis of the right middle cerebral artery–M2 segment (arrow), (B)
post-angioplasty and stenting with no residual stenosis using Resolute Onyx Drug-Eluting Stents 2 × 8mm. Two-dimensional parametric parenchymal blood flow
demonstrates the difference in blood flow pre- (C) and post-angioplasty and stenting (D).
lesions 16.7% of procedures (Figure 1). Moreover, more distal
lesions (middle cerebral artery M2 segment) within small vessel
diameter were treated using the smallest profile of R-onyx DES
in the market (2× 8mm) with high technical success (Figure 2),
and 52.6% of the procedures were performed within 7 days of the
last stroke. Also, several studies in the literature (7–9) reported
higher rates of periprocedural complications than the present
study with a mean age of studied population lower than that
demonstrated in our case series.
A major concern for using bare-metal stents has been the
rate of ISR which is reported to be ∼24 to 45% (13, 25).
Previous studies demonstrated several clinical and anatomical
predictors of ISR after intracranial stenting including younger
age, diabetes mellitus, long lesions, and stenting of small
vessels (13, 25, 26). Because ISR is associated with a high
rate of recurrent neurologic events (27), DES treatment of
sICAD could be more effective especially if associated with
the aforementioned risk factors. DES has less incidence of
ISR (24); the underlying pathophysiological mechanism of this
is inhibition of vessel overreaction after injury and reduction
of neointimal thickness which is achieved by delivery of
antiproliferative drugs (28).
The technological advances of R-onyx DES provide the unmet
needs of intracranial stenting, and the thin strut thickness
remains a crucial characteristic in stent platform, demonstrating
better device conformability, easier navigability, and lesser strut
malapposition. Also, thin struts are associated with low levels
of inflammation at the lesion site resulting in rapid and almost
complete arterial re-endothelialization and reduced neointimal
growth (29). Furthermore, the slim 2-mm stent enables stenting
of a small target vessel diameter which is associated with a high
incidence of vessel injury, difficult accessibility, and higher rates
of ISR. Despite the poor visibility of the slim-profile DES that has
ultrathin struts under X-ray images, R-onyx DES was designed
with a platinum–iridium core and a cobalt alloy shell to enhance
its radiopacity (30).
The new technology of R-onyx DES could be a step forward
in the treatment of sICAD if large prospective multicenter trials
corroborate our results. The ongoing randomized clinical trial
(31) of using dual antiplatelet therapy only for 1 month followed
by single antiplatelet therapy after R-onyx DES implantation in
patients undergoing percutaneous coronary intervention with
high bleeding risk will likely be helpful in determining the
adequate duration of antiplatelet regimen in a similar subgroup
of sICAD patients.
Our study has all the typical limitations inherent of any single-
center retrospective analysis. In addition, the small sample size
where only 18 patients were included limits the generalizability
of our findings. Similarly, only 50% of patients had follow-
up imaging which limited the power to prove the efficacy in
preventing ISR. However, the main aim of this study is to
identify the periprocedural safety and technical success of the
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deployment of a new DES that might help in the treatment
of sICAD.
CONCLUSION
The present case series demonstrate that R-onyx DES can be
used in the treatment of sICAD with different types of lesions
with high procedural safety and technical success rates. Large
multicenter studies are needed to further evaluate procedural
safety, restenosis rates, and long-term efficacy.
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